Search Results

April 2022 Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization --Design Pharmaceuticals, a company redesigning small molecule drug discovery, today announced the closing Design Pharmaceuticals’ platform is based on ultrahigh-throughput technologies that biomine drug-like

If your team is designing covalent or tight-binding candidates, these principles reduce surprises and Designing for penetration —balance on/off rates to reach inner tissue, not just peripheries. Watch our new trailers for a preview of expert-led GPCR training designed for scientists and drug hunters Jens Carlsson shares how structure-based design, molecular dynamics, and smart collaboration turn models Kenakin… sorely needed in the field." — DrGPCR University Attendee 🚀 Join now — and learn to design

April 2022 "SAN DIEGO, April 12, 2022 — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization

Evi Kostenis "Pharmacist by training - PhD in Pharmacology - Postdoc at the NIH with Dr. Pharmacology at 7TM Pharma in Denmark; Full professor, department chair and director of the institute for pharmaceutical

These webinars are designed for scientists who want deep, data-driven discussion rather than surface-level chemists working on receptor targets • Structural biologists • Translational scientists • Biotech and pharmaceutical and graduate researchers entering drug discovery If you work directly with receptor systems, ligand design The content is highly relevant for biotech and pharmaceutical scientists. These programs are designed for scientists seeking advanced, mechanism-focused training in GPCR biology

Explore structure-based design of purinergic GPCR modulators with NIH scientist Kenneth A. . < Back Structure-Based Design of Modulators of Purinergic GPCRs March 12, 2026 at 2:00:00 PM 🔒 Watch The session is designed for PhD scientists, postdoctoral researchers, and industry professionals interested His research focuses on developing computational pipelines for rational ligand design targeting therapeutically